Anthropic CEO says the company will not bend to business or political pressure on AI safety as it makes its Nasdaq debut at a $1.5 trillion valuation.

"I believe sufficiently powerful AI working in concert with humans could compress a century of scientific and medical progress into a decade," Anthropic CEO Dario Amodei said at the company's Nasdaq opening-bell ceremony on Thursday, outlining how artificial intelligence could accelerate research into diseases, drug development and new treatments.
Amodei, who co-founded Anthropic with his sister Daniela Amodei and other researchers, said scientists were already using AI across areas such as protein folding, drug design, cancer genetics and clinical trial administration to accelerate work that would have taken considerably longer.
Drawing on his earlier career in biology, he spoke about the complexity involved in understanding diseases and developing treatments. He also referred to the long journey from scientific discoveries to approved medicines, including the years it took to develop the first treatment for a disease using CRISPR gene-editing technology.
However, Amodei cautioned that these applications were still producing early results and that experiments and clinical trials would continue to take time. He said AI could help accelerate these processes but would not eliminate the need for scientific validation.
Alongside the potential benefits, Amodei stressed that advanced AI carries significant risks, including misuse by individuals and nation states, economic disruption and the possibility of losing control over AI systems.
"There is a gigantic difference between how AI will go if we pay little attention to safety versus how it will go if we are obsessed with safety," he said.
He added that Anthropic would determine the pace of development and deployment based on safety considerations rather than commercial or political demands.
"We will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control. We will not bend to either business nor political pressure," Amodei said.
He said the company's safeguards include measures against biological and cybersecurity risks, alignment training and testing, and techniques to better understand and steer the behaviour of AI models.
Anthropic President and co-founder Daniela Amodei also highlighted the company's approach to safety and public benefit. She said Anthropic had established an AI safety team before launching its first product and had chosen not to use advertising to fund Claude.
Anthropic is a public benefit corporation, which requires it to weigh public interest alongside shareholder returns, she said.
The remarks came as Anthropic made its Nasdaq debut after pricing its IPO at $83 per share, valuing the company at approximately $1.5 trillion on a fully diluted basis. The offering of 980 million shares is expected to raise around $81.3 billion, making it the largest IPO by proceeds on record.
Anthropic's Nasdaq debut came amid a volatile session on Wall Street. The major US indices initially rallied after the opening bell, but the gains subsequently faded, with the Dow Jones Industrial Average down 1.03% at 49,683.25 and the S&P 500 declining 0.46% to 7,290.19 at 10:55 a.m. ET. The Nasdaq Composite was marginally lower at 24,420.09, down 0.04%.
Meanwhile, Anthropic shares were still awaiting their first public trade under the ticker ANT. The latest market indication put the potential opening price at around $104, approximately 25% above the IPO price of $83, although the opening price remained subject to change.